Overview

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2013-03-18

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

SCRI Development Innovations, LLC

Treatments:

Antibodies, Monoclonal
Bevacizumab
Leucovorin